FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
Fact checked by: Ashling Wahner , Cheney Gazzam Baltz Listen 0:00 / 0:00 Key Takeaways FDA accelerated approval covers ALK-positive NSCLC after alectinib, or after ≥ 2 prior ALK TKIs plus platinum chemotherapy in unresectable locally advanced or metastatic disease. ALKOVE-1 post-alectinib cohort (n = 67) demonstrated 49% ORR, with…